-
May 13 |
Diagnostics World | For diagnostic labs, 2025 is a “big, complicated year” that began with a milestone “win” for laboratories when a U.S. District Court decision vacated a Food and Drug Administration (FDA) final rule that would have regulated all laboratory-developed tests (LDTs) as medical devices. Despite that win, there is no shortage of concerns and challenges facing the industry, including unknowns about the final shape of the federal reconciliation package on Capitol Hill.
More
-
May 08 |
Diagnostics World | The stethoscope, despite being more than 200 years old, is not an easily retired diagnostic device. It remains symbolic of the medical profession, even if many physicians no longer wear them and those that do are not particularly good at using them.
More
-
May 06 |
Diagnostics World | Cleveland Diagnostics announced the results of a new independent study published in Urology; Illumina and Tempus AI collaborate to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation; LinusBio announced a new partnership with the BRAIN Foundation to support advancing autism biomarker research and facilitating early identification and intervention of autism spectrum disorder; and more.
More
-
May 02 |
Diagnostics World | One of the most important tools we have to reduce mortality from cancer is early detection. Mammograms have had a significant impact in improving outcomes for patients with breast cancer, and colonoscopies have done the same for patients with colorectal cancer. But despite broad recognition of the importance of early cancer detection, our ability to screen for a wide range of cancers is quite limited. In fact, there are only five cancers for which Medicare is directed to pay for screening: breast, cervical, colon, lung, and prostate.
More
-
Apr 30 |
Diagnostics World | Cleveland Diagnostics announced the results of a new independent study published in Urology; Illumina and Tempus AI collaborate to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation; LinusBio announced a new partnership with the BRAIN Foundation to support advancing autism biomarker research and facilitating early identification and intervention of autism spectrum disorder; and more.
More
-
Apr 29 |
Diagnostics World | Atsena will advance their lead program, ATSN-201, for the treatment of a genetic condition that is typically diagnosed in childhood and leads to blindness later in life; Merida Biosciences plan to develop antibody-like therapeutics to help treat multiple diseases; and more.
More
-
Apr 23 |
Diagnostics World | Over the past few years, a multidisciplinary team of experts has been spreading the news that an abnormality of the heart’s left atrium (LA), known as LA myopathy, can be a marker of elevated risk of stroke and dementia—even in the absence of atrial fibrillation (AFib). The current “gap in the field” is that there is no established way to characterize the condition.
More
-
Apr 22 |
Diagnostics World | The clinical relevance and limitations of so-called “lab-in-a-box” (LIAB) diagnostics, which surged in popularity during the COVID pandemic, have since that time been under considerable scrutiny, most notably among investors still spooked by the notorious Theranos scandal. One of the more enduring problems among LIAB developers is that they tend to get “blinded by the beauty” of their technology.
More
-
Apr 17 |
Diagnostics World | Researchers at The University of Texas at El Paso (UTEP) are developing a point-of-care device for diagnosing colorectal cancer which, like blood glucose devices, uses electrochemical sensors. The microchip electrode features an immunosensor that detects disease biomarkers in a drop of blood, opening the possibility of an accessible, inexpensive test for the nation’s second leading cause of cancer-related deaths.
More
-
Apr 16 |
Diagnostics World | Magnetic flexible endoscopes (MFEs) have up to now had a few disadvantages limiting their use inside the human body for performing virtual biopsies, notably navigation-related difficulties related to their traditional cylindrical shape. These robot-assisted devices use magnetic forces to propel and maneuver through lumens like the colon, but rotation happens in only two directions that limits the scope's ability to effectively perform procedures.
More
-
May 12 |
• Prof Heather Pinkett and Dr Dafydd Owen to lead ELRIG’s flagship event
• Drug Discovery returns to Liverpool, 21–22 October 2025 to celebrate “A Festival of Life Science”
• Event supported by VisitBritain showcases UK life science sector and extends international reach
More
-
May 09 |
Longhorn Vaccines and Diagnostics Validates Efficacy of PrimeStore® Molecular Transport Medium (MTM) to Inactivate Deadly Pathogens in NIH Study
More
-
May 09 |
Sunnen's cutting-edge bore gaging system offers unmatched precision, versatility, and efficiency for high-precision measurement needs in medical device manufacturing.
More
-
May 09 |
Proscia's Concentriq AP-Dx*software platform was recognized for innovation, performance, value, and impact as digital pathology increasingly enters the mainstream.
More
-
May 09 |
More
-
May 01 |
The findings from the newly presented research suggest that earlier diagnosis through interventions such as Dxcover’s proprietary PANAROMIC™ liquid biopsy platform has the potential to reduce the risk of brain cancer mortality by 18-28%.
The data was presented on 30 April at the Cancer in Primary Care Research International (Ca-PRI) Conference 2025 and the American Association of Cancer Research (AACR) Annual Meeting 2025.
These world first findings use data from a retrospective cohort study of 1,196 patients.
More
-
Apr 30 |
Gifthealth, a technology-driven pharmacy care company dedicated to making prescription access easier and more affordable, is pleased to announce the appointment of Chip Parkinson as its new Chief Executive Officer.
More
-
Apr 29 |
Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing, today announced their collaboration with the Child Neurology Society (CNS) as an official 2025-2026 genetic testing partner. For patients and families facing neurodevelopmental disorders (NDD), epilepsy, and other neurological concerns, comprehensive genetic testing is an important step to ending the diagnostic odyssey.
More
-
Apr 29 |
More
-
Apr 24 |
SPINEstat™, a novel, first-in-class diagnostic blood test for axial spondyloarthritis (axSpA), has received UKCA marking and is now listed as an IVD in the United Kingdom. This milestone expands access to an important new tool that addresses the long-standing diagnostic challenges associated with axSpA. AxSpA is an inflammatory autoimmune condition of the spine, often misdiagnosed as persistent lower back pain for 7–10 years before accurate detection. Earlier diagnosis is essential to prevent irreversible spinal damage and to improve outcomes. SPINEstat™ offers physicians an objective, clinically validated biomarker to support early and accurate axSpA diagnosis, marking a major advancement in autoimmune diagnostics across the UK.
More
View more articles